Omentin-1 vs Ziconotide
Head-to-head comparison of Omentin-1 (Omentin-1 (Intelectin-1, ITLN1)) and Ziconotide (ω-Conotoxin MVIIA (ziconotide)) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Omentin-1 | Ziconotide |
|---|---|---|
| Category | Diabetes & Metabolic | Pain Management |
| Full Name | Omentin-1 (Intelectin-1, ITLN1) | ω-Conotoxin MVIIA (ziconotide) |
| Molecular Weight | ~35 kDa | 2639.1 Da |
| Half-Life | hours | approximately 4.5 hours |
| Amino Acids | 313 | 25 |
| Typical Dose | No approved human dose; research use only | 0.5-19.2 mcg/day |
| Route | IV|SC | Intrathecal |
| Purity | ≥98% | ≥98% |
| Studies Count | 82 | 500 |
| Research Status | Pre-clinical | Approved |
Omentin-1 Benefits
- ✓insulin sensitivity
- ✓glucose uptake
- ✓lipid handling
Ziconotide Benefits
- ✓strong non-opioid analgesia
- ✓effective for refractory neuropathic pain
- ✓opioid-sparing option
- ✓intrathecal delivery allows targeted action
Omentin-1 Dosing
not established|not established
Ziconotide Dosing
start 0.5 mcg/day intrathecal|titrate by 0.5 mcg/day no more than 2 times weekly|max 19.2 mcg/day in labeling
Omentin-1 Side Effects
- ⚠unknown
- ⚠immunogenicity risk
Ziconotide Side Effects
- ⚠dizziness
- ⚠confusion
- ⚠ataxia
Research Overview
Omentin-1
Lower omentin-1 levels are often associated with obesity, insulin resistance, and metabolic syndrome. Research continues on its use as a biomarker and as a mechanistic lead for AMPK-linked metabolic interventions.
Ziconotide
Clinical studies and post-marketing data support ziconotide as an analgesic for severe chronic pain that does not respond to conventional therapy. Research focuses on balancing analgesic efficacy with neuropsychiatric tolerability and careful dose titration.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.